Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009 and APX2014
Phentolamine Ophthalmic Solution 0.75%
Scientific Posters and Publications
Partnerships
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia
Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Press Releases
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
All Releases
Financial Releases
Rexahn Signs Agreement with National Institute of Neurological Disorders and Stroke
Feb 5, 2007
Monte Jade Names Rexahn Pharmaceuticals 2006 Biotechnology Company of the Year
Jan 19, 2007
1...
35
36
37
38
39
40
41
42
43
44